Global GLP-1 Market Size is valued at USD 50.0 Billion in 2024 and is predicted to reach USD 141.9 Billion by the year 2034 at an 11.1% CAGR during the forecast period for 2025-2034.
The glucagon-like peptide-1 receptor (GLP1R) is a crucial target in treating type 2 diabetes and obesity, given its significant role in regulating blood sugar levels and appetite. GLP-1, a hormone produced in the gut, enhances insulin secretion from pancreatic beta cells in response to glucose, increases insulin expression, and reduces beta-cell apoptosis. It also lowers glucagon secretion, slows stomach emptying, promotes satiety, and improves glucose disposal in peripheral tissues. Medications known as GLP-1 agonists, including exenatide, liraglutide, and semaglutide, activate the GLP1R, effectively lowering blood sugar levels and facilitating weight loss in individuals with type 2 diabetes.
The global GLP-1 receptor agonist market is rapidly expanding due to the rising prevalence of type 2 diabetes and obesity, which have become major public health concerns. With diabetes diagnoses significantly increasing and obesity rates skyrocketing, there is a growing demand for effective treatments that manage blood sugar levels and promote weight loss. GLP-1 agonist medications, which target the GLP-1 receptor to regulate insulin, glucagon, and appetite, offer a promising therapeutic approach to these health challenges. As the prevalence of these metabolic disorders continues to rise, the GLP-1 receptor agonist market is set for substantial growth in the coming years.
The GLP-1 market is segmented by type of molecule, active compound used, type of glp-1 agonist drugs, type of agonist, route of administration, target indication. By type of molecule the market is segmented into biologics and small molecules, by active compound used market is categorized into dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds. By type of glp-1 agonist drugs market is categorized into long-acting glp-1 agonist and short-acting glp-1 agonist. By type of agonist the market is single-agonist, dual-agonist and tri-agonist, by route of administration market is categorized into oral and parenteral, by target indication market is categorized into Alzheimer’s disease, non-alcoholic steatohepatitis, obesity, sleep apnea, type 2 diabetes.
The semaglutide segment is a key driver of growth in the GLP-1 receptor agonist market due to its effectiveness and popularity. Marketed as Ozempic and Wegovy, semaglutide has proven highly effective in lowering blood sugar levels in type 2 diabetes patients and promoting significant weight loss in individuals with obesity. Its approval for obesity treatment has broadened its market appeal, especially as global obesity rates rise. Additionally, innovative formulations and administration methods, such as once-weekly injections and oral options, enhance patient convenience and adherence. Semaglutide also offers notable cardiovascular benefits, making it an attractive option for patients with type 2 diabetes and obesity who face increased heart disease risks.
The obesity segment is the fastest-growing area in the GLP-1 receptor agonist market due to several key factors. First, the global prevalence of obesity is rising, with over 40% of adults in the U.S. classified as clinically obese, driving demand for effective weight loss treatments like GLP-1 agonists. Additionally, regulatory approvals for drugs such as semaglutide (Wegovy) specifically for obesity treatment have expanded the patient population significantly. GLP-1 agonists have also shown strong efficacy in clinical trials, with patients achieving an average weight loss of 15-25%, further promoting rapid adoption. Moreover, increasing insurance coverage and affordability of these medications are enhancing patient access, facilitating their utilization in managing obesity.
The APAC region is leading the global GLP-1 receptor agonist market, characterized by rapid growth driven by countries such as China, Japan, and India. This expansion is fueled by a growing healthcare sector, a large target patient population, and significant unmet clinical needs for diabetes and obesity treatments. The rising prevalence of type 2 diabetes and obesity in these countries is increasing demand for effective GLP-1 agonist therapies. Additionally, major pharmaceutical companies are innovating and developing tailored solutions for the APAC market to meet these rising demands. Although specific market share data is limited, the APAC region is recognized as the fastest-growing and a key contributor to the overall GLP-1 receptor agonist market.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 50.0 Billion |
|
Revenue Forecast In 2034 |
USD 141.9 Billion |
|
Growth Rate CAGR |
CAGR of 11.1% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
AstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Gmax Biopharm, Hanmi Pharmaceutical, Innogen, Novo Nordisk, PegBio, Pfizer, QL Biopharma, Roche, Sanofi, Sciwind Biosciences, Tonghua Dongbao Pharmaceutical, Viking Therapeutics, Vivani, vTv Therapeutic |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global 3D Printed Satellite Market Snapshot
Chapter 4. Global 3D Printed Satellite Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type of Molecule Estimates & Trend Analysis
5.1. by Type of Molecule & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Molecule:
5.2.1. Biologics
5.2.2. Small Molecules
Chapter 6. Market Segmentation 2: by Active Compound Used Estimates & Trend Analysis
6.1. by Active Compound Used & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Active Compound Used:
6.2.1. Dulaglutide
6.2.2. Liraglutide
6.2.3. Orforglipron
6.2.4. Retatrutide
6.2.5. Semaglutide
6.2.6. Survodutide
6.2.7. Tirzepatide
6.2.8. Other Active Compounds
Chapter 7. Market Segmentation 3: by Type of GLP-1 Agonist Drugs Estimates & Trend Analysis
7.1. by Type of GLP-1 Agonist Drugs & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of GLP-1 Agonist Drugs:
7.2.1. Long-acting GLP-1 Agonist
7.2.2. Short-acting GLP-1 Agonist
Chapter 8. Market Segmentation 4: by Type of Agonist Estimates & Trend Analysis
8.1. by Type of Agonist & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Agonist:
8.2.1. Single agonist
8.2.2. Dual agonist
8.2.3. Tri-agonist
Chapter 9. Market Segmentation 5: by Route of Administration Estimates & Trend Analysis
9.1. by Route of Administration & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:
9.2.1. Oral
9.2.2. Parenteral
Chapter 10. Market Segmentation 6: by Target Indication Estimates & Trend Analysis
10.1. by Target Indication & Market Share, 2024 & 2034
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Indication:
10.2.1. Alzheimer’s Disease
10.2.2. Non-Alcoholic Steatohepatitis
10.2.3. Obesity
10.2.4. Sleep Apnea
10.2.5. Type 2 Diabetes
Chapter 11. 3D Printed Satellite Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
11.1.2. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
11.1.3. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
11.1.4. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
11.1.5. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.1.6. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
11.1.7. North America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.2. Europe
11.2.1. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
11.2.2. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
11.2.3. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
11.2.4. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
11.2.5. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.2.6. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
11.2.7. Europe 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.3. Asia Pacific
11.3.1. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
11.3.2. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
11.3.3. Asia-Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
11.3.4. Asia-Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
11.3.5. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.3.6. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
11.3.7. Asia Pacific 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.4. Latin America
11.4.1. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
11.4.2. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
11.4.3. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
11.4.4. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
11.4.5. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.4.6. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
11.4.7. Latin America 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.5. Middle East & Africa
11.5.1. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Molecule, 2021-2034
11.5.2. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Active Compound Used, 2021-2034
11.5.3. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of GLP-1 Agonist Drugs, 2021-2034
11.5.4. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Type of Agonist, 2021-2034
11.5.5. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.5.6. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
11.5.7. Middle East & Africa 3D Printed Satellite Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. AstraZeneca
12.2.2. Biolingus
12.2.3. Boehringer Ingelheim
12.2.4. D&D Pharmatech
12.2.5. Eli Lilly
12.2.6. Gmax Biopharm
12.2.7. Hanmi Pharmaceutical
12.2.8. Innogen
12.2.9. Novo Nordisk
12.2.10. PegBio
12.2.11. Pfizer
12.2.12. QL Biopharma
12.2.13. Roche
12.2.14. Sanofi
12.2.15. Sciwind Biosciences
12.2.16. Tonghua Dongbao Pharmaceutical
12.2.17. Viking Therapeutics
12.2.18. Vivani
12.2.19. vTv Therapeutic
12.2.20. Other Prominent Players
GLP-1 Market by Type of Molecule -
GLP-1 Market by Active Compound Used -
GLP-1 Market by Type of GLP-1 Agonist Drugs -
GLP-1 Market by Type of Agonist -
GLP-1 Market by Route of Administration-
GLP-1 Market by Target Indication-
GLP-1 Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
